CAR T-Cell Therapy

Following a report of low CD4-positive T cell counts in a patient’s peripheral blood, the FDA placed a clinical hold on a phase 1 study of LB1901.

Considering later lines of treatment such as chimeric antigen receptor T-cell therapy, make it difficult for chimeric antigen receptor T-cell therapy to find its optimal place in the armamentarium.

Clinical trial findings presented during the ASH annual meeting have the potential to change the management of diffuse large B-cell lymphoma, according to John M. Burke, MD.

The label for axicabtagene ciloleucel now includes prophylactic corticosteroids use in all approved indications.

Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

With the rapid advancement of CAR T, there is no doubt that many patients in the future will reap the benefits.

Liso-cel was found to improve quality of life in patients with large B-cell lymphoma compared with standard of care.

Cilta-Cel produced an overall response of 95% in patients with heavily pretreated multiple myeloma.

Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.

Early study results indicate that YTB323 may be effective and safe for the treatment of patients with diffuse large B-cell lymphoma.

Tisagenlecleucel failed to improve event-free survival in the second-line setting of relapsed or refractory aggreesve B-cell non-Hodgkin lymphoma versus standard-of-care.

Updated results from CARTITUDE-1 reveal deep and durable response to ciltacabtagene autoleucel treatment in patients with multiple myeloma.

According to findings of the ZUMA-12, axicabtagene ciloleucel can induce durable responses in patients with large B-cell lymphoma.

Compared with standard of care, ciltacabtagene autoleucel produces better responses in the setting of heavily pretreated multiple myeloma.

A novel chimeric antigen receptor T-cell agent will now be developed in the United States following an orphan drug designation granted by the FDA.

To address an unmet medical need for agents to treat B-cell malignancies, the FDA has granted an RMAT designation to CTX110, a chimeric antigen receptor T-cell therapy.

Eleven months after a 43-year-old woman with diffuse large B-cell lymphoma completed chimeric antigen receptor T-cell therapy, she complained of fever, night sweats, and back pain.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.

Following treatment with chimeric antigen receptor T-cell therapy, patients with relapsed or refractory large B-cell lymphoma require more options. Investigators are now evaluating an interleukin-17 agent.

The CAR T-cell therapy may provide another therapy option for patients with large B-cell lymphoma.

All clinical trials of allogeneic CAR T cells developed by Allogene Therapeutics, Inc have been halted by the FDA pending an investigation of a chromosomal abnormality event.

Michael R. Bishop, MD, discusses chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.

In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Mehdi Hamadani, MD and Bertram Glass, MD recently debated on the role of allogeneic hematopoietic stem cell transplant for the treatment of aggressive B-cell lymphoma now that chimeric antigen receptor T cells have entered the landscape.

Lee Greenberger, PhD, evaluates novel immunotherapies in non-Hodgkin lymphoma for World Lymphoma Awareness Day.